Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209–249 (2021).
Google ScholarÂ
Yang, W. J. et al. Updates on global epidemiology, risk and prognostic factors of gastric cancer. World J. Gastroenterol. 29, 2452–2468 (2023).
Google ScholarÂ
Abnet, C. C. et al. A prospective study of BMI and risk of oesophageal and gastric adenocarcinoma. Eur. J. Cancer 44, 465–471 (2008).
Google ScholarÂ
Lagergren, J., Bergström, R., Lindgren, A. & Nyrén, O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N. Engl. J. Med. 340, 825–831 (1999).
Google ScholarÂ
Sundar, R. et al. Gastric cancer. Lancet 405, 2087–2102 (2025).
Google ScholarÂ
Wong, M. C. S. et al. Global incidence and mortality of gastric cancer, 1980-2018. JAMA Netw. Open 4, e2118457 (2021).
Google ScholarÂ
Thrift, A. P., Wenker, T. N. & El-Serag, H. B. Global burden of gastric cancer: epidemiological trends, risk factors, screening and prevention. Nat. Rev. Clin. Oncol. 20, 338–349 (2023).
Google ScholarÂ
Zhang, F., Yan, Y. & Ge, C. Frailty as a predictor of adverse outcomes in patients with gastric cancer: a systematic review and meta-analysis of 75,357 patients. Ageing Res. Rev. 101, 102528 (2024).
Google ScholarÂ
Laurén, P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma.: attempt at a histo-clinical classification. Acta Pathol. Microbiol. Scand. 64, 31–49 (1965).
Google ScholarÂ
Bass, A. J. et al. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513, 202–209 (2014).
Google ScholarÂ
Shitara, K. et al. Nivolumab plus chemotherapy or ipilimumab in gastroesophageal cancer: exploratory biomarker analyses of a randomized phase 3 trial. Nat. Med. 31, 1519–1530 (2025).
Google ScholarÂ
Janjigian, Y. Y. et al. Genomic landscape of late-stage gastric cancer: analysis from KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 studies. JCO Precis. Oncol. 9, e2400456 (2025).
Google ScholarÂ
Catenacci, D. V. T. et al. Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): a phase II study evaluating an individualized treatment strategy for metastatic disease. Cancer Discov. 11, 308–325 (2021).
Google ScholarÂ
Lee, J. et al. Tumor genomic profiling guides patients with metastatic gastric cancer to targeted treatment: the VIKTORY umbrella trial. Cancer Discov. 9, 1388–1405 (2019).
Google ScholarÂ
Rha, S. Y. et al. Bemarituzumab (BEMA) plus chemotherapy for advanced or metastatic FGFR2b-overexpressing gastric or gastroesophageal junction cancer (G/GEJC): FORTITUDE-101 phase III study results [abstract LBA10]. Ann. Oncol. 36, S1620 (2025).
Google ScholarÂ
Wagner, A. D. et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst. Rev. 3, CD004064 (2010).
Boku, N. et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol. 10, 1063–1069 (2009).
Google ScholarÂ
Koizumi, W. et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 9, 215–221 (2008).
Google ScholarÂ
Cunningham, D. et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N. Engl. J. Med. 358, 36–46 (2008).
Google ScholarÂ
Koizumi, W. et al. Phase II study of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer (G-SOX study). Ann. Oncol. 21, 1001–1005 (2010).
Google ScholarÂ
Yamada, Y. et al. Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer. Ann. Oncol. 26, 141–148 (2015).
Google ScholarÂ
Zaanan, A. et al. TFOX versus FOLFOX in first-line treatment of patients with advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma (PRODIGE 51- FFCD-GASTFOX): an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 26, 732–744 (2025).
Google ScholarÂ
Van Cutsem, E. et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the v325 Study Group. J. Clin. Oncol. 24, 4991–4997 (2006).
Google ScholarÂ
Al-Batran, S. E. et al. The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: a randomised trial of the Arbeitsgemeinschaft internistische Onkologie (FLOT65+). Eur. J. Cancer 49, 835–842 (2013).
Google ScholarÂ
Hall, P. S. et al. Efficacy of reduced-intensity chemotherapy with oxaliplatin and capecitabine on quality of life and cancer control among older and frail patients with advanced gastroesophageal cancer: the GO2 phase 3 randomized clinical trial. JAMA Oncol. 7, 869–877 (2021).
Google ScholarÂ
Janjigian, Y. Y. et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 398, 27–40 (2021).
Google ScholarÂ
Rha, S. Y. et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 24, 1181–1195 (2023).
Google ScholarÂ
Qiu, M. Z. et al. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial. BMJ 385, e078876 (2024).
Google ScholarÂ
Moehler, M. et al. Concordance between the PD-L1 tumor area positivity score and combined positive score for gastric or esophageal cancers treated with tislelizumab. Mod. Pathol. 38, 100793 (2025).
Google ScholarÂ
Kang, Y.-K. et al. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 23, 234–247 (2022).
Google ScholarÂ
Xu, J. et al. Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: the ORIENT-16 randomized clinical trial. JAMA 330, 2064–2074 (2023).
Google ScholarÂ
Zhang, X. et al. First-line sugemalimab plus chemotherapy for advanced gastric cancer: the GEMSTONE-303 randomized clinical trial. JAMA 333, 1305–1314 (2025).
Google ScholarÂ
Postow, M. A., Sidlow, R. & Hellmann, M. D. Immune-related adverse events associated with immune checkpoint blockade. N. Engl. J. Med. 378, 158–168 (2018).
Google ScholarÂ
Lordick, F. et al. Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann. Oncol. 33, 1005–1020 (2022).
Google ScholarÂ
Lordick, F., Candia Montero, L., Castelo-Branco, L., Pentheroudakis, G., Sessa, C. & Smyth, E. C. ESMO gastric cancer living guideline v1.4. ESMO https://www.esmo.org/guidelines/living-guidelines/esmo-living-guideline-gastric-cancer (2024).
Shah, M. A. et al. Immunotherapy and targeted therapy for advanced gastroesophageal cancer: ASCO guideline. J. Clin Oncol. 41, 1470–1491 (2023).
Google ScholarÂ
Shen, L. et al. First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial. Nat. Med. 31, 1163–1170 (2025).
Google ScholarÂ
Hegewisch-Becker, S. et al. First-line nivolumab and relatlimab plus chemotherapy for gastric or gastroesophageal junction adenocarcinoma: the phase II RELATIVITY-060 study. J. Clin. Oncol. 42, 2080–2093 (2024).
Google ScholarÂ
Rha, S. Y. et al. EDGE-Gastric Arm A1: phase II study of domvanalimab (D), zimberelimab (Z), and FOLFOX in first-line (1L) advanced gastroesophageal (GE) cancer [abstract 130MO]. Ann. Oncol. 35, S1455 (2024).
Google ScholarÂ
Peng, Z. et al. Phase III study of SHR-1701 versus placebo in combination with chemo as first-line (1L) therapy for HER2-negative gastric/gastroesophageal junction adenocarcinoma (G/GEJA) [abstract LBA60]. Ann. Oncol. 35, S1250 (2024).
Google ScholarÂ
Luchini, C. et al. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach. Ann. Oncol. 30, 1232–1243 (2019).
Google ScholarÂ
Cristescu, R. et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat. Med. 21, 449–456 (2015).
Google ScholarÂ
Chao, J. et al. Assessment of pembrolizumab therapy for the treatment of microsatellite instability-high gastric or gastroesophageal junction cancer among patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 clinical trials. JAMA Oncol. 7, 895–902 (2021).
Google ScholarÂ
Kawakami, H. et al. Phase II study (NO LIMIT, WJOG13320G) of first-line nivolumab plus low-dose ipilimumab for microsatellite instability-high advanced gastric or esophagogastric junction cancer. J. Clin. Oncol. 43, 2184–2195 (2025).
Google ScholarÂ
Bang, Y.-J. et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376, 687–697 (2010).
Google ScholarÂ
Janjigian, Y. Y. et al. Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: A European and USA International collaborative analysis. Ann. Oncol. 23, 2656–2662 (2012).
Google ScholarÂ
Bartley, A. N., Washington, M. K., Ismaila, N. & Ajani, J. A. HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline summary from the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. J. Oncol. Pract. 13, 53–57 (2017).
Google ScholarÂ
Wolff, A. C. et al. Human epidermal growth factor receptor 2 testing in breast cancer. Arch. Pathol. Lab. Med. 147, 993–1000 (2023).
Google ScholarÂ
Shitara, K. et al. Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial. Nat. Publ. Group. 30, 1933–1942 (2024).
Google ScholarÂ
Janjigian, Y. Y. et al. Pembrolizumab in HER2-positive gastric cancer. N. Engl. J. Med. 391, 1360–1362 (2024).
Google ScholarÂ
Shitara, K. et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N. Engl. J. Med. 382, 2419–2430 (2020).
Google ScholarÂ
Van Cutsem, E. et al. Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study. Lancet Oncol. 24, 744–756 (2023).
Google ScholarÂ
Shitara, K. et al. Trastuzumab deruxtecan or ramucirumab plus paclitaxel in gastric ancer. N. Engl. J. Med. 393, 336–348 (2025).
Google ScholarÂ
Janjigian, Y. Y. et al. Trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2-positive (HER2+) esophageal, gastric or gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03 (DG-03) [abstract 1401O]. Ann. Oncol. 35, S878 (2024).
Google ScholarÂ
Shen, L. et al. Disitamab vedotin (DV) plus toripalimab (Tor) and chemotherapy (C)/trastuzumab (Tra) as first-line (1L) treatment of patients (pts) with HER2-expressing locally advanced or metastatic (la/m) gastric cancer [abstract]. J. Clin. Oncol. 43, LBA4012 (2025).
Google ScholarÂ
Janjigian, Y. Y. et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. Lancet 402, 2197–2208 (2023).
Google ScholarÂ
Wei, Q. et al. Spatiotemporal quantification of HER2-targeting antibody–drug conjugate bystander activity and enhancement of solid tumor penetration. Clin. Cancer Res. 30, 984–997 (2024).
Google ScholarÂ
Li, J. et al. Updated results of HLX22 plus trastuzumab and XELOX for first-line treatment of human epidermal growth factor receptor 2 (HER2)-positive locally advanced or metastatic gastric/gastroesophageal junction cancer (G/GEJC) [abstract]. J. Clin. Oncol. 43, e16021 (2025).
Elimova, E. et al. Zanidatamab + chemotherapy as first-line treatment for HER2-expressing metastatic gastroesophageal adenocarcinoma (mGEA) [abstract]. J. Clin. Oncol. 41, 347 (2023).
Google ScholarÂ
Elimova, E. et al. Zanidatamab + chemotherapy (CT) ± tislelizumab for first-line (1L) HER2-positive (HER2+) locally advanced, unresectable, or metastatic gastroesophageal adenocarcinoma (mGEA): primary analysis from HERIZON-GEA-01 [abstract]. J. Clin. Oncol. 44 suppl. 2, LBA285 (2026).
Google ScholarÂ
Sahin, U. et al. Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development. Clin Cancer Res. 14, 7624–7634 (2008).
Google ScholarÂ
Kubota, Y. et al. Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer. ESMO Open 8, 100762 (2023).
Google ScholarÂ
Shah, M. A. et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat. Med. 29, 2133–2141 (2023).
Google ScholarÂ
Shitara, K. et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet 401, 1655–1668 (2023).
Google ScholarÂ
Shitara, K. et al. Global prevalence of claudin 18 isoform 2 in tumors of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma. Gastric Cancer 27, 1058–1068 (2024).
Google ScholarÂ
Pellino, A. et al. Association of CLDN18 protein expression with clinicopathological features and prognosis in advanced gastric and gastroesophageal junction adenocarcinomas. J. Pers. Med. 11, 1095 (2021).
Google ScholarÂ
Choi, E., Shin, J., Ryu, M. H., Kim, H. D. & Park, Y. S. Heterogeneity of claudin 18.2 expression in metastatic gastric cancer. Nat. Res. 14, 17648 (2024).
Google ScholarÂ
Klempner, S. J. et al. Preliminary safety and efficacy of givastomig, a novel claudin 18.2/4-1BB bispecific antibody, in combination with nivolumab and mFOLFOX in metastatic gastroesophageal carcinoma (mGEC) [abstract 388MO]. Ann. Oncol. 36, S151–S152 (2025).
Google ScholarÂ
Wainberg, Z. A. et al. Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol. 23, 1430–1440 (2022).
Google ScholarÂ
Su, X. et al. FGFR2 amplification has prognostic significance in gastric cancer: results from a large international multicentre study. Br. J. Cancer 110, 967–975 (2014).
Google ScholarÂ
Satoh, T. et al. Phase 2 study of futibatinib in patients with gastric or gastroesophageal junction cancer harboring FDFR2 amplifications. Eur. J. Cancer 218, 115262 (2025).
Google ScholarÂ
Catenacci, D. V. T. et al. Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 18, 1467–1482 (2017).
Google ScholarÂ
Shah, M. A. et al. Effect of fluorouracil, leucovorin, and oxaliplatin with or without onartuzumab in HER2-negative, MET-positive gastroesophageal adenocarcinoma: the METGastric randomized clinical trial. JAMA Oncol. 3, 620–627 (2017).
Google ScholarÂ
Finisguerra, V. et al. MET is required for the recruitment of anti-tumoural neutrophils. Nature. 522, 349–353 (2015).
Google ScholarÂ
Humbert, M. et al. Protective autophagy is involved in resistance towards MET inhibitors in human gastric adenocarcinoma cells. Biochem. Biophys. Res. Commun. 431, 264–269 (2013).
Google ScholarÂ
Kim, M. A. et al. EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number. Histopathology. 52, 738–746 (2008).
Google ScholarÂ
Lordick, F. et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol. 14, 490–499 (2013).
Google ScholarÂ
Waddell, T. et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol. 14, 481–489 (2013).
Google ScholarÂ
Shen, Y. C. et al. Phase II multicentered study of low-dose everolimus plus cisplatin and weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin as first-line treatment for patients with advanced gastric cancer. Oncology. 87, 104–113 (2014).
Google ScholarÂ
Ohtsu, A. et al. Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study. J. Clin. Oncol. 31, 3935–3943 (2013).
Google ScholarÂ
Lorenzen, S. et al. Phase III randomized, double-blind study of paclitaxel with and without everolimus in patients with advanced gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC). Int. J. Cancer 147, 2493–2502 (2020).
Google ScholarÂ
Kim, J.-W. et al. PIK3CA mutations are associated with increased tumor aggressiveness and Akt activation in gastric cancer. Ocotarget 8, 90948–90958 (2017).
Google ScholarÂ
Wilke, H. et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 15, 1224–1235 (2014).
Google ScholarÂ
Fuchs, C. S. et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 383, 31–39 (2014).
Google ScholarÂ
Ohtsu, A. et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J. Clin. Oncol. 29, 3968–3976 (2011).
Google ScholarÂ
Fuchs, C. S. et al. Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 20, 420–435 (2019).
Google ScholarÂ
Janjigian, Y. Y. et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature. 600, 727–730 (2021).
Google ScholarÂ
Sato, S. et al. Clinical characterization of FGFR2b expression in patients with advanced gastric or gastroesophageal junction adenocarcinoma. ESMO Open 10, 105322 (2025).
Google ScholarÂ
Janjigian, Y. Y. et al. First-line nivolumab plus chemotherapy for advanced gastric gastroesophageal junction, and esophageal adenocarcinoma: 3-year follow-up of the phase III CheckMate 649 trial. J. Clin. Oncol. 42, 2012–2020 (2024).
Google ScholarÂ
Lorenzen, S. et al. FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel — results from the phase II RAMIRIS study of the German Gastric Cancer Study Group at AIO. Eur. J. Cancer 165, 48–57 (2022).
Google ScholarÂ
Lorenzen, S. et al. Ramucirumab plus irinotecan/leucovorin/5-FU versus ramucirumab plus paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy: the phase II/III RAMIRIS study (AIO-STO-0415). BMC Cancer 23, 561 (2023).
Google ScholarÂ
Kang, J. H. et al. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J. Clin. Oncol. 30, 1513–1518 (2012).
Google ScholarÂ
Shitara, K. et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 19, 1437–1448 (2018).
Google ScholarÂ
Randon, G. et al. Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy in patients with advanced HER2-negative gastric or gastro-oesophageal junction cancer (ARMANI): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 25, 1539–1550 (2024).
Google ScholarÂ
Shitara, K. et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet 392, 123–133 (2018).
Google ScholarÂ
Chung, H. C. et al. Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE-063): a randomized, open-label, phase 3 trial in Asian patients. Cancer 128, 995–1003 (2022).
Google ScholarÂ
Lee, C. K. et al. Second-line chemoimmunotherapy with nivolumab and paclitaxel in immune-related biomarker-enriched advanced gastric cancer: a multicenter phase Ib/II study. Gastric Cancer 27, 118–130 (2024).
Google ScholarÂ
Nakajima, T. E. et al. Multicenter phase I/II study of nivolumab combined with paclitaxel plus ramucirumab as second-line treatment in patients with advanced gastric cancer. Clin. Cancer Res. 27, 1029–1036 (2021).
Google ScholarÂ
Muro, K. et al. Pan-Asian adapted ESMO clinical practice guidelines for the management of patients with metastatic gastric cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. Ann. Oncol. 30, 19–33 (2019).
Google ScholarÂ
Kang, Y. K. et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390, 2461–2471 (2017).
Google ScholarÂ
US Food and Drug Administration. Highlights of prescribing information: OPDIVO (nivolumab) injection. FDA.gov https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125554s091lbl.pdf (2021).
US Food and Drug Administration. Highlights of prescribing information: KEYTRUDA (pembrolizumab) injection. FDA.gov https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf (2023).
Ogitani, Y. et al. DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. Clin Cancer Res. 22, 5097–5108 (2016).
Google ScholarÂ
Cortés, J. et al. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N. Engl. J. Med. 386, 1143–1154 (2022).
Google ScholarÂ
Modi, S. et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N. Engl. J. Med. 382, 610–621 (2020).
Google ScholarÂ
Kim, J. et al. XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer. Nature. 538, 114–117 (2016).
Google ScholarÂ
Bardia, A. et al. Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer. N. Engl. J. Med. 391, 2110–2122 (2024).
Google ScholarÂ
Yamaguchi, K. et al. Trastuzumab deruxtecan in anti-human epidermal growth factor receptor 2 treatment-naive patients with human epidermal growth factor receptor 2-low gastric or gastroesophageal junction adenocarcinoma: exploratory cohort results in a phase II trial. J. Clin. Oncol. 41, 816–825 (2023).
Google ScholarÂ
Janjigian, Y. Y., Raoufmoghaddam, S., Sztachelska, M., Winter, M. & Das, S. Phase 1b/2, open-label dose-escalation and -expansion study evaluating trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with HER2+ and HER2-low gastric cancer (GC): DESTINY-Gastric03 (DG-03) [abstract]. J. Clin. Oncol. 42, TPS424 (2024).
Google ScholarÂ
Wang, Y. et al. Disitamab vedotin (RC48) plus toripalimab for HER2-expressing advanced gastric or gastroesophageal junction and other solid tumours: a multicentre, open label, dose escalation and expansion phase 1 trial. eClinicalMedicine 68, 102415 (2024).
Google ScholarÂ
Ter Veer, E. et al. Continuation of trastuzumab beyond progression in HER2-positive advanced esophagogastric cancer: a meta-analysis. Acta Oncol. 57, 1599–1604 (2018).
Google ScholarÂ
Makiyama, A. et al. Randomized, phase II study of trastuzumab beyond progression in patients with HER2-positive advanced gastric or gastroesophageal junction cancer: WJOG7112G (T-ACT study). J. Clin. Oncol. 38, 1919–1927 (2020).
Google ScholarÂ
Thuss-Patience, P. C. et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncol. 18, 640–653 (2017).
Google ScholarÂ
Satoh, T. et al. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN — a randomized, phase III study. J. Clin. Oncol. 32, 2039–2049 (2014).
Google ScholarÂ
Lorenzen, S. et al. Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Eur. J. Cancer 51, 569–576 (2015).
Google ScholarÂ
Sanchez-Vega, F. et al. EGFR and MET amplifications determine response to HER2 inhibition in ERBB2-amplified esophagogastric cancer. Cancer Discov. 9, 199–209 (2019).
Google ScholarÂ
Saeki, H. et al. Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab (KSCC1604). Eur. J. Cancer 105, 41–49 (2018).
Google ScholarÂ
Klempner, S. J. et al. ILUSTRO: phase II multicohort trial of zolbetuximab in patients with advanced or metastatic claudin 18.2-positive gastric or gastroesophageal junction adenocarcinoma. Clin. Cancer Res. 29, 3882–3891 (2023).
Google ScholarÂ
Türeci, O. et al. A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study. Ann. Oncol. 30, 1487–1495 (2019).
Google ScholarÂ
Türeci, Ö, Mitnacht-Kraus, R., Wöll, S., Yamada, T. & Sahin, U. Characterization of zolbetuximab in pancreatic cancer models. Oncoimmunology 8, e1523096 (2019).
Google ScholarÂ
Peng, Z. et al. A phase Ib/II study of ASKB589 (anti-claudin 18.2 [CLDN18.2] monoclonal antibody) combined with CAPOX and PD-1 inhibitor as first-line treatment for locally advanced, relapsed and metastatic gastric/gastro-esophageal junction (G/GEJ) adenocarcinoma [abstract]. J. Clin. Oncol. 42, 317 (2024).
Google ScholarÂ
Gong, J. et al. A phase I/II study of FG-M108 plus capecitabine and oxaliplatin (CAPOX) as first-line (1L) treatment for patients with CLDN18.2+/HER2- advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma [abstract 1433P]. Ann. Oncol. 35, S892 (2024).
Google ScholarÂ
Zheng, L. et al. Safety and preliminary efficacy results of IBI389, an anti-CLDN18.2/CD3 bispecific antibody, in patients with solid tumors and gastric or gastro-esophageal tumors: A phase 1 dose escalation and expansion study [abstract]. J. Clin. Oncol. 42, 2519 (2024).
Google ScholarÂ
Ruan, D. Y. et al. Claudin 18.2-targeting antibody-drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): a multicentre, open-label, single-arm, phase 1 trial. Lancet Oncol. 26, 227–238 (2025).
Google ScholarÂ
Botta, G. P. et al. CLDN18.2 chimeric antigen receptor T cell therapy for patients with advanced gastric and pancreatic adenocarcinoma: results of ELIMYN18.2 phase 1b clinical trial [abstract]. J. Clin. Oncol. 42, 356 (2024).
Google ScholarÂ
Qi, C. et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. Nat. Med. 28, 1189–1198 (2022).
Google ScholarÂ
Qi, C. et al. Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician’s choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial. Lancet 405, 2049–2060 (2025).
Google ScholarÂ
Cohen, R. et al. Association of primary resistance to immune checkpoint inhibitors in metastatic colorectal cancer with misdiagnosis of microsatellite instability or mismatch repair deficiency status. JAMA Oncol. 5, 551–555 (2019).
Google ScholarÂ
Colle, R. et al. Pseudoprogression in patients treated with immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer. Eur. J. Cancer 144, 9–16 (2021).
Google ScholarÂ
Kim, S. T. et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat. Med. 24, 1449–1458 (2018).
Google ScholarÂ
Grasso, C. S. et al. Genetic mechanisms of immune evasion in colorectal cancer. Cancer Discov. 8, 730–749 (2018).
Google ScholarÂ
Shin, D. S. et al. Primary resistance to PD-1 blockade mediated by JAK1/2 mutations. Cancer Discov. 7, 188–201 (2017).
Google ScholarÂ
Lu, C. et al. DNA sensing in mismatch repair-deficient tumor cells is essential for anti-tumor immunity. Cancer Cell 39, 96–108.e6 (2021).
Google ScholarÂ
Llosa, N. J. et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov. 5, 43–51 (2015).
Google ScholarÂ
Bauer, K. et al. Dendritic cell and macrophage infiltration in microsatellite-unstable and microsatellite-stable colorectal cancer. Fam. Cancer 10, 557–565 (2011).
Google ScholarÂ
Picco, G. et al. Werner helicase is a synthetic-lethal vulnerability in mismatch repair-deficient colorectal cancer refractory to targeted therapies, chemotherapy, and immunotherapy. Cancer Discov. 11, 1923–1937 (2021).
Google ScholarÂ
Dong, K. et al. Prevalence and detection methodology for preliminary exploration of NTRK fusion in gastric cancer from a single-center retrospective cohort. Hum. Pathol. 148, 87–92 (2024).
Google ScholarÂ
Shi, M. et al. Identification of RET fusions in a Chinese multicancer retrospective analysis by next-generation sequencing. Cancer Sci. 113, 308–318 (2022).
Google ScholarÂ
Ambrosini, M. et al. ALK inhibitors in patients with ALK fusion-positive GI cancers: an international data set and a molecular case series. JCO Precis. Oncol. 6, e2200015 (2022).
Google ScholarÂ
Marabelle, A. et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 21, 1353–1365 (2020).
Google ScholarÂ
Kroese, T. E. et al. European clinical practice guidelines for the definition, diagnosis, and treatment of oligometastatic esophagogastric cancer (OMEC-4). Eur. J. Cancer 204, 114062 (2024).
Google ScholarÂ
Al-Batran, S.-E. et al. Effect of chemotherapy/targeted therapy alone vs. chemotherapy/targeted therapy followed by radical surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction: The IKF-575/RENAISSANCE phase III trial [abstract]. J. Clin. Oncol. 42, LBA4001 (2024).
Google ScholarÂ
Thomassen, I. et al. Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival and risk factors. Int. J. Cancer 134, 622–628 (2014).
Google ScholarÂ
Gwee, Y. X. et al. Integration of genomic biology into therapeutic strategies of gastric cancer peritoneal metastasis. J. Clin. Oncol. 40, 2830–2845 (2022).
Google ScholarÂ
Jacquet, P. & Sugarbaker, P. H. Peritoneal–plasma barrier. Cancer Treat. Res. 82, 53–63 (1996).
Google ScholarÂ
Zhao, J. J. et al. Spatially resolved niche and tumor microenvironmental alterations in gastric cancer peritoneal metastases. Gastroenterology. 167, 1384–1398.e4 (2024).
Google ScholarÂ
Yu, W., Whang, I., Chung, H. Y., Averbach, A. & Sugarbaker, P. H. Indications for early postoperative intraperitoneal chemotherapy of advanced gastric cancer: results of a prospective randomized trial. World J. Surg. 25, 985–990 (2001).
Google ScholarÂ
Kang, Y.-K. et al. Enhanced efficacy of postoperative adjuvant chemotherapy in advanced gastric cancer: results from a phase 3 randomized trial (AMC0101). Cancer Chemother. Pharmacol. 73, 139–149 (2013).
Google ScholarÂ
Ishigami, H. et al. Phase III trial comparing intraperitoneal and intravenous paclitaxel plus S-1 versus cisplatin plus S-1 in patients with gastric cancer with peritoneal metastasis: PHOENIX-GC trial. J. Clin. Oncol. 36, 1922–1929 (2018).
Google ScholarÂ
Yan, C. et al. Intraperitoneal and intravenous paclitaxel plus S-1 versus intravenous paclitaxel plus S-1 in gastric cancer patients with peritoneal metastasis: results from the multicenter, randomized, phase 3 DRAGON-01 trial [abstract]. J. Clin. Oncol. 43, 327 (2025).
Google ScholarÂ
Yonemura, Y. et al. Multidisciplinary therapy for treatment of patients with peritoneal carcinomatosis from gastric cancer. World J. Gastrointest. Oncol. 2, 85–97 (2010).
Google ScholarÂ
Sugarbaker, P. H. Intraperitoneal chemotherapy and cytoreductive surgery for the prevention and treatment of peritoneal carcinomatosis and sarcomatosis. Semin. Surg. Oncol. 14, 254–261 (1998).
Google ScholarÂ
Butensky, S. D. et al. Consensus guideline for the management of gastric cancer with synchronous peritoneal metastases. Ann. Surg. Oncol. https://doi.org/10.1245/s10434-025-17361-2 (2025).
Google ScholarÂ
D’Angelo, S. P. et al. Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial. Lancet 403, 1460–1471 (2024).
Google ScholarÂ
Rohaan, M. W. et al. Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma. N. Engl. J. Med. 387, 2113–2125 (2022).
Google ScholarÂ
Stancovski, I. et al. Targeting of T lymphocytes to Neu/HER2-expressing cells using chimeric single chain Fv receptors. J. Immunol. 151, 6577–6582 (1993).
Google ScholarÂ
Zhou, Y. et al. Clinical results of a phase 1 trial evaluating a HER2 directed CAR-T product selective for the tumor microenvironment (TME) in patients with GI and other solid tumor malignancies [abstract]. J. Clin. Oncol. 43, 449 (2025).
Google ScholarÂ
Feng, Z. et al. Potent suppression of neuroendocrine tumors and gastrointestinal cancers by CDH17CAR T cells without toxicity to normal tissues. Nat. Cancer 3, 581–594 (2022).
Google ScholarÂ
Carneiro, B. et al. Phase 1 clinical update of allogeneic invariant natural killer T cells (iNKTs), agenT-797, alone or in combination with pembrolizumab or nivolumab in patients with advanced solid tumors [abstract]. Cancer Res. 83, CT275 (2023).
Google ScholarÂ
Adusumilli, P. S. et al. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Sci. Transl. Med. 6, 261ra151 (2014).
Google ScholarÂ
Murad, J. P. et al. Effective targeting of TAG72+ peritoneal ovarian tumors via regional delivery of CAR-engineered T cells. Front. Immunol. 9, 2268 (2018).
Google ScholarÂ
Adusumilli, P. S. et al. A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab. Cancer Discov. 11, 2748–2763 (2021).
Google ScholarÂ
Choo, J. et al. A phase I trial of intraperitoneal (IP) mesothelin (MSLN)-targeted CAR T-cell therapy in patients with MSLN-positive esophagogastric cancer (EGC) with peritoneal carcinomatosis [abstract]. J. Clin. Oncol. 43, TPS513 (2025).
Google ScholarÂ
Kono, K. et al. Dendritic cells pulsed with HER-2/neu-derived peptides can induce specific T-cell responses in patients with gastric cancer. Clin. Cancer Res. 8, 3394–3400 (2002).
Google ScholarÂ
Sundar, R. et al. A phase I/Ib study of OTSGC-A24 combined peptide vaccine in advanced gastric cancer. BMC Cancer 18, 332 (2018).
Google ScholarÂ
Ott, P. A. et al. A phase Ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer. Cell 183, 347–362.e24 (2020).
Google ScholarÂ
Braiteh, F. et al. A phase Ia study to evaluate RO7198457, an individualized neoantigen specific immunotherapy (iNeST), in patients with locally advanced or metastatic solid tumors [abstract]. Cancer Res. 80, CT169 (2020).
Google ScholarÂ
Braun, D. A. et al. A neoantigen vaccine generates antitumour immunity in renal cell carcinoma. Nature 639, 474–482 (2025).
Google ScholarÂ
Weber, J. S. et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet 403, 632–644 (2024).
Google ScholarÂ
Diaz-Montero, C. M. et al. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol. Immunother. 58, 49–59 (2009).
Google ScholarÂ
Saxena, M., van der Burg, S. H., Melief, C. J. M. & Bhardwaj, N. Therapeutic cancer vaccines. Nat. Rev. Cancer 21, 360–378 (2021).
Google ScholarÂ
Tobias, J. et al. Phase II trial of HER-Vaxx, a B-cell peptide-based vvaccine, in HER2-overexpressing advanced gastric cancer patients under platinum-based chemotherapy (HERIZON). Clin. Cancer Res. 30, 4044–4054 (2024).
Google ScholarÂ
Besse, B. et al. Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1. Ann. Oncol. 34, 920–933 (2023).
Google ScholarÂ
Ma, L. et al. Enhanced CAR–T cell activity against solid tumors by vaccine boosting through the chimeric receptor. Science 365, 162–168 (2019).
Google ScholarÂ
Ma, L. et al. Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity. Cell 186, 3148–3165.e20 (2023).
Google ScholarÂ
Mackensen, A. et al. CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial. Nat. Med. 29, 2844–2853 (2023).
Google ScholarÂ
Ishihara, M. et al. A phase 1 trial of NY-ESO-1-specific TCR-engineered T-cell therapy combined with a lymph node-targeting nanoparticulate peptide vaccine for the treatment of advanced soft tissue sarcoma. Int. J. Cancer 152, 2554–2566 (2023).
Google ScholarÂ
Sun, L. et al. Smart nanoparticles for cancer therapy. Signal. Transduct. Target. Ther. 8, 418 (2023).
Google ScholarÂ
Lumish, M. A. et al. Noninvasive assessment of human epidermal growth factor receptor 2 (HER2) in esophagogastric cancer ising 89Zr-trastuzumab PET: a pilot study. J. Nucl. Med. 64, 724–730 (2023).
Google ScholarÂ
Yang, Y. et al. Claudin 18.2-targeted 68Ga-labeled NODAGA-SNA014 for gastric cancer imaging by PET [abstract]. Cancer Res. 85, 1339 (2025).
Google ScholarÂ
Esfahani, S. A. et al. Development of a fibrin-targeted theranostic for gastric cancer. Sci. Transl. Med. 16, eadn7218 (2024).
Google ScholarÂ
Qin, C. et al. 68Ga-DOTA-FAPI-04 PET/MR in the evaluation of gastric carcinomas: comparison with 18F-FDG PET/CT. J. Nucl. Med. 63, 81–88 (2022).
Google ScholarÂ
Nakamura, Y. et al. Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies. Nat. Med. 26, 1859–1864 (2020).
Google ScholarÂ
George, M. A. et al. Clinical performance of Signatera Genome assay in a cohort of patients (pts) with solid tumors [abstract]. J. Clin. Oncol. 43, 3142 (2025).
Google ScholarÂ
Martin-Alonso, C. et al. Priming agents transiently reduce the clearance of cell-free DNA to improve liquid biopsies. Science 383, eadf2341 (2024).
Google ScholarÂ
Nakamura, Y. et al. ctDNA-based molecular residual disease and survival in resectable colorectal cancer. Nat. Med. 30, 3272–3283 (2024).
Google ScholarÂ
Tie, J. et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer. N. Engl. J. Med. 386, 2261–2272 (2022).
Google ScholarÂ
Black, J. R. M. et al. Ultrasensitive ctDNA detection for preoperative disease stratification in early-stage lung adenocarcinoma. Nat. Med. 31, 70–76 (2025).
Google ScholarÂ
Yang, J. et al. Deep sequencing of circulating tumor DNA detects molecular residual disease and predicts recurrence in gastric cancer. Cell Death Dis. 11, 346 (2020).
Google ScholarÂ
Maron, S. B. et al. Circulating tumor DNA sequencing analysis of gastroesophageal adenocarcinoma. Clin. Cancer Res. 25, 7098–7112 (2019).
Google ScholarÂ
Huffman, B. M. et al. Analysis of circulating tumor DNA to predict risk of recurrence in patients with esophageal and gastric cancers. JCO Precis. Oncol. 6, e2200420 (2022).
Google ScholarÂ
Openshaw, M. R. et al. Longitudinal monitoring of circulating tumour DNA improves prognostication and relapse detection in gastroesophageal adenocarcinoma. Br. J. Cancer 123, 1271–1279 (2020).
Google ScholarÂ
Ji, J. et al. Circulating tumor DNA testing in curatively resected colorectal cancer and salvage resection. JAMA Netw. Open 7, e2452661 (2024).
Google ScholarÂ
Tie, J. et al. Circulating tumor DNA-guided adjuvant therapy in locally advanced colon cancer: the randomized phase 2/3 DYNAMIC-III trial. Nat. Med. 31, 4291–4300 (2025).
Google ScholarÂ
Powles, T. et al. ctDNA guiding adjuvant immunotherapy in urothelial carcinoma. Nature 595, 432–437 (2021).
Google ScholarÂ
Powles, T. et al. ctDNA-guided adjuvant atezolizumab in muscle-invasive bladder cancer. N. Engl. J. Med. 393, 2395–2408 (2025).
Google ScholarÂ
Fundytus, A. et al. Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional survey. Lancet Oncol. 22, 1367–1377 (2021).
Google ScholarÂ
Bamodu, O. A. & Chung, C. C. Cancer care disparities: overcoming barriers to cancer control in low- and middle-income countries. JCO Glob. Oncol. 10, e2300439 (2024).
Google ScholarÂ
Mudumba, R. et al. Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for patients with human epidermal growth factor receptor 2 positive metastatic breast cancer in the United States. Value Health 27, 153–163 (2024).
Google ScholarÂ
Yeong, J. et al. Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy. Gastric Cancer 25, 741–750 (2022).
Google ScholarÂ
Klempner, S. J. et al. PD-L1 immunohistochemistry in gastric cancer: comparison of combined positive score and tumor area positivity across 28-8, 22C3, and SP263 assays. JCO Precis. Oncol. 8, e2400230 (2024).
Google ScholarÂ
